Becton, Dickinson and Co. vs Eli Lilly & Co.
BDX vs LLY — side-by-side comparison from reported financials. BDX leads 2, LLY leads 10 of 12 comparable metrics.
Becton, Dickinson and Co.
BDX · Healthcare
$183.75+0.55%Strained
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | BDX | LLY |
|---|---|---|
| Price | $183.75 | $1 177.20 |
| Market cap | $50.0B | $1.05T |
| Revenue (TTM) | $20.1B | $79.7B |
| Revenue growth | +5.0% | +31.7% |
| Net margin | 4.7% | 33.5% |
| Free cash flow | $2.73B | $18.2B |
| Net cash (debt) | ($18.5B) | ($35.2B) |
| 1-year price return | -2.8% | +37.6% |
| P/E | 53.1 | 41.6 |
| P/E vs own history (cheap-side %) | 31% | 88% |
| Dividend yield | 2.34% | 0.52% |
| Return on equity | 4% | 93% |
| Altman Z-score | 1.95 | 7.10 |
| CV checks passed | 7 of 11 | 11 of 11 |
| Employees | 72,000 | 50,000 |
Full résumé-style profiles: BDX CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.